Vaccinex, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VCNX research report →
Price Chart
About the company
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options.
- CEO
- Maurice Zauderer
- IPO
- 2018
- Employees
- 25
- HQ
- Rochester, NY, US
Get TickerSpark's AI analysis on VCNX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.05M
- P/E
- -0.57
- PEG
- -0.00
- P/S
- 1.43
- P/B
- -0.39
- EV/EBITDA
- -1.61
- Div Yield
- 0.00%
- Gross Margin
- 98.33%
- Op Margin
- -249.74%
- Net Margin
- -251.07%
- ROE
- 104.38%
- ROIC
- 252.27%
Latest fiscal year · YoY change
- Revenue
- $2.10M+248.6%
- Gross Profit
- $2.06M+242.8%
- Op Income
- $-5,232,000
- Net Income
- $-5,260,000+71.8%
- EPS
- $-1.97+77.8%
- OCF Growth
- +60.2%
- FCF Growth
- +60.1%
- 52W High
- $1.50
- 52W Low
- $0.31
- 50D MA
- $1.00
- 200D MA
- $1.04
- Beta
- 0.67
- RSI (14)
- 58
- Avg Volume
- 1.22K
No earnings-call transcripts are available for VCNX yet.
- Free Float
- 44.2%
- Shares Outstanding
- 2.68M
- Float Shares
- 1.18M
of shares held by institutions
2 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Telemetry Investments, L.L.C. | 416.00K | ▼ 74.00K |
| Hnp Capital LLC | 10.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 24 | FRIEDBERG ALBERT | other | 30,756 |
| Nov 14, 24 | FRIEDBERG ALBERT | other | 584,646 |
| Nov 14, 24 | Zauderer Maurice | other | 46,153 |
| Sep 18, 24 | Zauderer Maurice | other | 35,715 |
| Sep 18, 24 | Zauderer Maurice | other | 9,768 |
| Sep 18, 24 | Zauderer Maurice | other | 29,557 |
| Sep 18, 24 | Zauderer Maurice | other | 38,610 |
| Sep 18, 24 | Zauderer Maurice | other | 170,475 |
| Sep 18, 24 | Zauderer Maurice | other | 35,715 |
| Sep 18, 24 | FRIEDBERG ALBERT | other | 25,723 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VCNX coverage
Recent articles, reports, and earnings notes.
No research on VCNX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VCNX report →SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
globenewswire.com · Oct 7
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
globenewswire.com · Jul 8
Vaccinex Reports 2025 Annual Financial Results
globenewswire.com · Apr 29
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX)
defenseworld.net · Dec 25
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
globenewswire.com · May 27
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
globenewswire.com · Apr 21
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
globenewswire.com · Mar 7
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.